Maze Therapeutics (MAZE) SEC Filings: History & Chart

Maze Therapeutics, Inc.(MAZE)

Biotechnology · South San Francisco, CA

$26.40-0.03 (-0.13%)

Delayed quote: Oct 6, 2026, 3:20 PM EDT

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

South San Francisco, CA

141 employees

www.mazetx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jason Coloma

View full financials

Form	Filing Date	Accepted	Document
4	Oct 2, 2026	Oct 2, 2026	View filing
4	Oct 2, 2026	Oct 2, 2026	View filing
4	Oct 1, 2026	Oct 1, 2026	View filing
4	Sep 8, 2026	Sep 8, 2026	View filing
144	Sep 4, 2026	Sep 4, 2026	View filing
4	Sep 4, 2026	Sep 4, 2026	View filing
4	Sep 4, 2026	Sep 4, 2026	View filing
4	Sep 4, 2026	Sep 4, 2026	View filing
4	Sep 4, 2026	Sep 4, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
144	Sep 2, 2026	Sep 2, 2026	View filing
144	Sep 2, 2026	Sep 2, 2026	View filing
144	Sep 2, 2026	Sep 2, 2026	View filing
144	Sep 2, 2026	Sep 2, 2026	View filing
144	Sep 1, 2026	Sep 1, 2026	View filing
4	Aug 31, 2026	Aug 31, 2026	View filing
4	Aug 17, 2026	Aug 17, 2026	View filing
4	Aug 17, 2026	Aug 17, 2026	View filing
3	Aug 17, 2026	Aug 17, 2026	View filing
3	Aug 17, 2026	Aug 17, 2026	View filing
8-K	Aug 17, 2026	Aug 17, 2026	View filing
4	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
144	Aug 3, 2026	Aug 3, 2026	View filing

SEC Filings

Recent Filings